Common Drug Review *



Submission Status

Product: Ciprodex Generic Name: ciprofloxacin hydrochloride & dexamethasone otic suspension

Manufacturer: Alcon Canada Inc.

Submission Type: Request for Advice

Date Submission Received: 2007-Jun-15 Date NOC Issued: 2004-May-10 Targeted CEDAC Meeting: 2007-Oct-17 **Priority Review Granted:** Not Requested

rargeted CEDAC Meeting: 2007-0017 Priority Review Granted: Not Requested					. Not Requested
	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	CDR Request for Advice Assessment - Review team formed and determines approach for responding to Request for Advice	10	2007-Jun-29	2007-Jun-21	ACP Request for Advice
2	CDR Reviewers' reports or other document completed as determined by CDR team i) Reviewers' Report sent to Manufacturer for comment ii) Documentation completed as required and sent to manufacturer for information only. (no comments required)	45	2007-Aug-27	2007-Jul-12	Documentation sent to manufacturer. No manufacturer comments required.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7			
4	Reviewers' Reply to Manufacturer's Comments Completed	7			
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2007-Oct-02	2007-Jul-13	
6	CEDAC Meeting		2007-Sep-19	2007-Sep-19	Request for Advice discussed at July 18, 2007 CEDAC meeting. Response to Request for Advice Pending. Response to Request for Advice placed on September 19, 2007 CEDAC meeting agenda.
7	Recommendation and Reasons for Recommendation or Response to Request for Advice sent to Drug Plans, ACP and Manufacturer	5	2007-Sep-26	2007-Sep-26	An embargoed CEDAC recommendation issued in response to this Request for Advice.
8 (a)	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2007-Oct-11	2007-Oct-11	
OR					
8 (b)	No Embargo Period if Request for Advice does not result in a Revised Recommendation or Reasons for Recommendation				
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2007-Oct-18	2007-Oct-18	Notice of Final Recommendation issued.
OR					
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
OR					
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

Reflects updates as of Thursday noon.

^{*} Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER submission is assessed. The target dates for this report are based on the CEDAC meeting schedule, which is posted on

www.cadth.ca
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.